Expression of both anti- and pro-apoptotic BCL2 members was heterogeneous with low BIM (BCL2L11) expression in all BCR-ABL + ALL lines and patient material (Figs. S1E, S1F and S1G). Here, BCL2L11 is linked to acute lymphoblastic leukemia.